The spiraling consequences underline the real-world harms from Donald Trump's upending of decades-old U.S. initiatives.

An aviation fuel company in Great Falls will soon receive its first installment of a nearly $1.7 billion loan from the ...

The judge said Regier consistently during the 2023 session denied relying on political considerations and told others he didn't know how to check the partisan lean of his proposed districts.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

For the final three months of 2024, Novo delivered sales of 85.68 billion Danish kroner (around $12 billion), a 30% increase from the same period in 2023. That haul helped Novo’s total sales for ...

Novo Nordisk’s blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday ...

Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...

In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial ...

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

Great Falls, describes Montana Medicaid expansion in its current form as a program that "gets people healthy, unaddicted and into the workforce." ...